Regeneron's Spike Not Tied to Pfizer-Anacor Deal, But It Doesn't Hurt

... treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema. The deal comes as Regeneron, a Tarrytown, N.Y.-based biotech company, works toward the expected launch of its eczema drug Dupilumab next year in collaboration with ...
http://ift.tt/1ssN2O4